$-0.12 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)

January 21, 2018 - By Maria Brooks

 $ 0.12 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)
Investors sentiment increased to 1.43 in Q3 2017. Its up 0.26, from 1.17 in 2017Q2. It is positive, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported.
Legal And General Grp Inc Public Limited Liability stated it has 12,663 shares or 0% of all its holdings. Blackrock reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Deutsche Retail Bank Ag owns 203,817 shares or 0% of their US portfolio. Piermont Capital Mngmt reported 0.09% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Kopp Investment Advisors Ltd Liability Company accumulated 0.2% or 12,020 shares. Pnc Financial Service has invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Bogle Invest Management Limited Partnership De stated it has 352,604 shares. Fmr Limited Liability Corporation holds 0% or 1.48M shares. Rhumbline Advisers, a Massachusetts-based fund reported 51,321 shares. Secor Cap Limited Partnership stated it has 94,272 shares or 0.16% of all its holdings. Aqr Capital Mgmt Llc holds 11,896 shares or 0% of its portfolio. Quantitative Mgmt Ltd Limited Liability Company owns 146,200 shares. Tiaa Cref Invest Mngmt Ltd Co invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Orbimed Advisors Ltd Llc reported 967,859 shares or 0.17% of all its holdings. Morgan Stanley reported 1.08M shares stake.

Since January 2, 2018, it had 0 insider purchases, and 4 insider sales for $3.36 million activity. The insider Birznieks Gunther sold $130,777. Kelly James Patrick sold $140,494 worth of stock or 9,155 shares. Polymeropoulos Mihael Hristos sold $2.93 million worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday, January 2.

Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $-0.12 EPS on February, 21.They anticipate $0.16 EPS change or 400.00 % from last quarter’s $0.04 EPS. After having $-0.10 EPS previously, Vanda Pharmaceuticals Inc.’s analysts see 20.00 % EPS growth. The stock increased 1.75% or $0.25 during the last trading session, reaching $14.5. About 328,764 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since January 21, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 21 analyst reports since September 2, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Thursday, August 3. On Monday, January 8 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, September 2. The firm has “Outperform” rating given on Monday, October 30 by Oppenheimer. Jefferies reinitiated the stock with “Buy” rating in Thursday, October 6 report. H.C. Wainwright maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Thursday, August 3 with “Buy” rating. As per Wednesday, October 21, the company rating was initiated by Brean Capital. The rating was maintained by Oppenheimer with “Buy” on Sunday, November 12. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Thursday, August 3 by Oppenheimer. Jefferies maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday, June 26 with “Buy” rating.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $651.45 million. The company's marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Another recent and important Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news was published by Prnewswire.com which published an article titled: “This Morning’s Technical Outlook on Biotech Stocks — Moleculin Biotech, Vanda …” on January 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: